Under this expanded agreement, Cellares will provide proof-of-concept manufacturing for a second Bristol Myers Squibb CAR-T cell therapy The announcement comes weeks after Cellares first indicated ...

Machine-learning analysis identifies factors predicting T cell collection efficiency in CAR T-cell therapy for DLBCL patients. Higher blood volume, not higher circulating T-cell numbers, correlates ...

SOUTH SAN FRANCISCO, Calif. & LONDON--(BUSINESS WIRE)--Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation ...

Manufacturing CAR T cell therapy—one of the most powerful weapons against certain blood cancers—has to date involved an elaborate process, through which doctors first extract a patient’s immune cells ...

See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. For decades, advanced medical breakthroughs have followed a familiar ...

After recalibrating its production strategy in the late 2010s to better meet the realities of the CAR-T market, Gilead Sciences’ Kite Pharma is preparing to hit the ground running with the potential ...

Chimeric antigen receptor T (CAR T) cell therapy represents a milestone in leukemia treatment. CAR T works by genetically engineering a chimeric antigen receptor on the surface of the patient's T ...

Safety and efficacy data from a phase 1 multicenter study evaluating rapcabtagene autoleucel, an investigational next-generation CD19-directed CAR-T cell therapy that is manufactured in 48 hours using ...